Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 5/20 | 1.00 |
| ▸ | SRC | P12931 | 5/20 | 0.51 |
| ▸ | BTK | Q06187 | 4/20 | 0.51 |
| ▸ | LYN | P07948 | 3/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30521696 | 0.87 | FYN (1.00) | FYNSRCBTKLYNSCN9A | |
| SCHEMBL18613278 | 0.87 | FYN (1.00) | FYNSRCBTKLYNSCN9A | |
| SCHEMBL16332376 | 0.81 | FYN (0.67) | FYNSRCBTKLYNCLK4 | |
| SCHEMBL16332690 | 0.80 | FYN (0.72) | FYNSRCBTKLYNFGFR1 | |
| SCHEMBL18613212 | 0.75 | FYN (1.00) | FYNSRCBTKFGFR1 | |
| SCHEMBL16373487 | 0.75 | FYN (0.65) | FYNCLK4USP2ALDH1A1CYP1A2 | |
| SCHEMBL16332684 | 0.74 | FYN (0.59) | FYNSRCFGFR1CYP1A2CYP3A4 | |
| SCHEMBL16332636 | 0.72 | FYN (0.60) | FYNSRCCDK9CDK5FGFR1 | |
| SCHEMBL16331911 | 0.71 | FYN (0.55) | FYNSRCBTKLYNFGFR1 | |
| SCHEMBL16332064 | 0.71 | FYN (0.88) | FYNSRCBTKLYNCLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2018-09-06 | — | — | US | claimed |
| US-20240041868-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2024-02-08 | — | — | US | disclosed |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | Pathways Neuro Pharma, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | Pathways Neuro Pharma, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | Pathways Neuro Pharma, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210030753-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2021-02-04 | — | — | US | disclosed |
| US-20210030753-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2021-02-04 | — | — | US | disclosed |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | Pathways Neuro Pharma, Inc. | 2020-06-23 | — | — | US | disclosed |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | Pathways Neuro Pharma, Inc. | 2020-06-23 | — | — | US | disclosed |
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2018-09-06 | — | — | US | disclosed |
| EP-3347462-A1 | METHODS, COMPOSITIONS, AND USES OF NOVEL FYN KINASE INHIBITORS | Lau, Warren C. (US) | 2018-07-18 | — | — | EP | disclosed |
| WO-2017044623-A1 | METHODS, COMPOSITIONS, AND USES OF NOVEL FYN KINASE INHIBITORS | LAU WARREN C (US) | 2017-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041868-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | FYN, LCK, PTK2B | FYN 1/4885SRC 9/4885BTK 116/4885 |
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | FYN, LCK, PTK2B | FYN 1/4885SRC 9/4885BTK 116/4885 |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | FYN, LCK, PTK2B | FYN 1/4885SRC 9/4885BTK 116/4885 |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | FYN, LCK, PTK2B | FYN 1/4885SRC 9/4885BTK 116/4885 |
| US-20210030753-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | FYN, LCK, PTK2B | FYN 1/4885SRC 9/4885BTK 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.